I-Liraglutide Anti-Diabetics for Blood Sugar Control CAS NO.204656-20-2
Imininingwane Yomkhiqizo
| I-CAS | 204656-20-2 | I-Molecular Formula | C172H265N43O51 |
| Isisindo samangqamuzana | 3751.20 | Ukubukeka | Emhlophe |
| Isimo Sesitoreji | Ukumelana nokukhanya, i-2-8 degree | Iphakheji | Isikhwama se-aluminium foil/vial |
| Ubumsulwa | ≥98% | Ezokuthutha | I-Cold Chain nokulethwa kwesitoreji esipholile |
Izithako zeLiraglutide
Isithako Esisebenzayo:
I-Liraglutide (i-analog ye-glucagon-like peptide-1 (GLP-1) yomuntu ekhiqizwa imvubelo ngobuchwepheshe bokuhlanganiswa kabusha kofuzo).
Igama Lekhemikhali:
I-Arg34Lys26-(N-e-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Ezinye Izithako:
I-Disodium Hydrogen Phosphate Dihydrate, i-Propylene Glycol, i-Hydrochloric Acid kanye/noma i-Sodium Hydroxide (njenge-pH Adjusters Kuphela), i-Phenol, Namanzi Omjovo.
Isicelo
Isifo sikashukela sohlobo 2
I-Liraglutide ithuthukisa ukulawulwa kweglucose yegazi. Yehlisa i-hyperglycemia ehlobene nokudla (emahoreni angama-24 ngemuva kokuphathwa) ngokwandisa ukukhiqizwa kwe-insulin (kuphela) lapho kudingwa ngokwandisa amazinga eglucose, ukubambezeleka ukuphuma kwesisu, nokucindezela ukukhiqizwa kweglucagon ye-prandial.
Ilungele iziguli ezinoshukela osegazini ongalawulwa kahle ngemuva komthamo omkhulu obekezelelwe we-metformin noma we-sulfonylureas kuphela. Isetshenziswa ngokuhlanganiswa ne-metformin noma i-sulfonylureas.
Isebenza ngendlela encike ku-glucose, okusho ukuthi izogqugquzela ukukhiqizwa kwe-insulin kuphela uma amazinga eglucose esegazini engaphezulu kokujwayelekile, okuvimbela "ukudumba ngokweqile". Ngakho-ke, kukhombisa ubungozi obuncane be-hypoglycemia.
Inamandla okuvimbela i-apoptosis futhi ikhuthaze ukukhiqizwa kabusha kwamaseli e-beta (okubonwa ezifundweni zezilwane).
Yehlisa isifiso sokudla futhi ivimbele ukuzuza kwesisindo somzimba, njengoba kukhonjisiwe ocwaningweni lwekhanda nekhanda ngokumelene ne-glimepiride.
Isenzo se-Pharmacological
I-Liraglutide iyi-analog ye-GLP-1 ene-97% yokulandelana kwe-homology ku-GLP-1 yomuntu, engabopha futhi yenze i-GLP-1 receptor isebenze. I-GLP-1 receptor iyimpoqo ye-GLP-1 yomdabu, i-endogenous incretin hormone ekhuthaza ukukhiqizwa kwe-insulin encike ekugxilweni kweglucose kumaseli e-pancreatic beta. Ngokungafani ne-GLP-1 yomdabu, amaphrofayili e-pharmacokinetic kanye ne-pharmacodynamic e-liraglutide kubantu alungele uhlobo lomthamo kanye ngosuku. Ngemuva komjovo we-subcutaneous, indlela yayo yokusebenza isikhathi eside ihlanganisa: ukuzihlanganisa okubambezela ukumuncwa; ukubopha ku-albumin; Ukuqina kwe-enzyme ephezulu futhi ngaleyo ndlela ende yesigamu sempilo ye-plasma.
Umsebenzi we-liraglutide uqondiswa ukuxhumana kwayo okukhethekile ne-GLP-1 receptor, okuholela ekwandeni kwe-cyclic adenosine monophosphate (cAMP). I-Liraglutide ivuselela ukukhiqizwa kwe-insulin ngendlela encike ekugxilweni kwe-glucose, kuyilapho yehlisa ukukhiqizwa kwe-glucagon ngokweqile ngendlela encike ekugxilweni kweglucose.
Ngakho-ke, lapho ushukela wegazi ukhuphuka, ukukhiqizwa kwe-insulin kuyavuselelwa, kuyilapho ukukhiqizwa kwe-glucagon kuvinjelwe. Ngokuphambene, i-liraglutide yehlisa ukukhiqizwa kwe-insulin ngesikhathi se-hypoglycemia ngaphandle kokuthinta ukukhiqizwa kwe-glucagon. Indlela ye-hypoglycemic ye-liraglutide ihlanganisa nokwelulwa kancane kwesikhathi sokuphuma kwesisu. I-Liraglutide yehlisa isisindo somzimba kanye nesisindo samafutha omzimba ngokunciphisa indlala nokudla kwamandla.
